📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Immunovant

1.1 - Company Overview

Immunovant Logo

Immunovant

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Immunovant

BlueSphere Bio Logo

BlueSphere Bio

HQ: United States Website
  • Description: Provider of TCXpress technology designed to unlock the potential of personalized T-cell therapy for the treatment of cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full BlueSphere Bio company profile →
Autolus Therapeutics Logo

Autolus Therapeutics

HQ: United Kingdom Website
  • Description: Provider of next-generation programmed T cell therapies for cancer, leveraging T-cell programming and manufacturing technology. Pipeline includes CAR T products such as obe-cel (obecabtagene autoleucel) for adult ALL; AUTO1/22 for pediatric ALL; AUTO4 (TRBC1) and AUTO5 (TRBC2) for peripheral T-cell lymphoma; AUTO6NG (GD2) for neuroblastoma and other solid tumors; and AUTO8 (BCMA/CD19) for multiple myeloma.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Autolus Therapeutics company profile →
Kite Pharma Logo

Kite Pharma

HQ: United States Website
  • Description: Provider of immune-based targeted cancer therapies, including personalized CAR T-cell treatments that stimulate patients' immune systems. Offerings include Yescarta for certain relapsed or refractory large B-cell lymphoma and follicular lymphoma, and Tecartus for relapsed or refractory mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Kite Pharma company profile →
Syntarga Logo

Syntarga

HQ: The Netherlands Website
  • Description: Provider of proprietary Antibody-Drug Conjugate technology and products for the treatment of cancer, leveraging cutting-edge chemistry capabilities and unique know-how to create its antibody empowering Potent Payload Technology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Syntarga company profile →
MacroGenics Logo

MacroGenics

HQ: United States Website
  • Description: Provider of immunotherapeutics, including antibody-drug conjugates and DART bispecifics targeting B7-H3, PD-1×CTLA-4 and CD123, to treat metastatic castration-resistant prostate cancer, advanced solid tumors, CD123-positive neoplasms (AML, MDS) and multiple cancers; programs include vobramitamab duocarmazine, lorigerlimab, MGD024, MGC026, MGC028 and enoblituzumab.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full MacroGenics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Immunovant

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Immunovant

2.2 - Growth funds investing in similar companies to Immunovant

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Immunovant

4.2 - Public trading comparable groups for Immunovant

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Immunovant

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Immunovant

What does Immunovant do?

Immunovant is a provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.

Who are Immunovant's competitors?

Immunovant's competitors and similar companies include BlueSphere Bio, Autolus Therapeutics, Kite Pharma, Syntarga, and MacroGenics.

Where is Immunovant headquartered?

Immunovant is headquartered in United States.

How many employees does Immunovant have?

Immunovant has 1,000 employees 🔒.

When was Immunovant founded?

Immunovant was founded in 2010 🔒.

What sector and industry vertical is Immunovant in?

Immunovant is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Immunovant

Who are the top strategic acquirers in Immunovant's sector and industry

Top strategic M&A buyers and acquirers in Immunovant's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Immunovant?

Top strategic M&A buyers groups and sectors for Immunovant include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Immunovant's sector and industry vertical

Which are the top PE firms investing in Immunovant's sector and industry vertical?

Top PE firms investing in Immunovant's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Immunovant's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Immunovant's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Immunovant's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Immunovant include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Immunovant's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Immunovant?

The key public trading comparables and valuation benchmarks for Immunovant include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Immunovant for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Immunovant with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Immunovant's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Immunovant with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Immunovant's' sector and industry vertical?

Access recent funding rounds and capital raises in Immunovant's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Immunovant